{"id":"placebo-for-ag-221","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3989908","moleculeType":"Small molecule","molecularWeight":"473.38"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"As a placebo, this product contains no active pharmaceutical ingredient and produces no direct molecular or therapeutic effect. It is used as a control arm in the phase 3 trial of AG-221 to establish efficacy and safety of the active drug through comparison against an inert comparator.","oneSentence":"This is a placebo control with no active pharmacological mechanism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:20.052Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in phase 3 trial for acute myeloid leukemia (AML) with IDH2 mutations (AG-221 indication)"}]},"trialDetails":[{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT03839771","phase":"PHASE3","title":"A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2019-03-01","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2","enrollment":968}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for AG-221","genericName":"Placebo for AG-221","companyName":"Stichting Hemato-Oncologie voor Volwassenen Nederland","companyId":"stichting-hemato-oncologie-voor-volwassenen-nederland","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control with no active pharmacological mechanism. Used for Control arm in phase 3 trial for acute myeloid leukemia (AML) with IDH2 mutations (AG-221 indication).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}